Market research
MBII Marrone Bio Innovations Inc
NASDAQ USD Materials
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 146M
- P/E ratio
- Not available
- Analyst target
- 1.38
- Dividend yield
- 0.0%
- Beta
- 0.35
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Materials
- Industry
- Chemicals
- ISIN
- US57165B1061
- Market cap
- 146M
- P/E ratio
- Not available
- Analyst target
- 1.38
- Dividend yield
- 0.0%
- Beta
- 0.35
About
About Marrone Bio Innovations Inc
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MBII discussion.
5 years, 4 months ago
Marrone Bio Innovations, Inc is currently in a long term downtrend where the price is trading 10.4% below its 200 day moving average.
From a valuation standpoint, the stock is 23.7% cheaper than other stocks from the Basic Materials sector with a price to sales ratio of 7.5.
Marrone Bio Innovations, Inc's total revenue sank by 98.5% to $100K since the same quarter in the previous year.
Its net income has increased by 100.0% to $-53 since the same quarter in the previous year.
Finally, its free cash flow fell by 48.5% to $-7M since the same quarter in the previous year.
Based on the above factors, Marrone Bio Innovations, Inc gets an overall score of 2/5.